Main Article Content


Rhabdomyosarcoma is the fifth most common type of soft tissue solid tumor in children and the most common in the last two decades. Rhabdomyosarcoma of the urogenital organ is a rare mesenchymal tumor, covering 22% of all Rhabdomyosarcoma cases. The two most common histologic types are alveolar and embryonal, whereas botryoid and spindle cells are rarely found. We reported a case of embryonal Rhabdomyosarcoma of the prostate. In this study, we improved the understanding of Embryonal Rhabdomyosarcoma of the prostate on 23 years old male who had a history of swelling in the perineal area and a history of falling from a height in the groin area 5 months before. The patient complains of the difficulty of urinating and hematuria one month after falling. We underwent drainage of the swelling area, found pus 100cc and took a sample for pathological examination. The result was embryonal rhabdomyosarcoma. Prostate volume was 122cc, PSA 5,32 and PSAD 0,04. The CT scan result was solid mass size 15x8x18 cm at perineum enhance to the pelvic cavity, push the bladder to the superior, rectum to posterior, and urethra posterior to the left side. We diagnosed this patient as Embryonal Rhabdomyosarcoma prostate T2bG1N0M0 (stage 3) group 3 and intermediate-risk group. The patient underwent VAC chemotherapy based on D.9803 (IRS V) protocol and planned radiotherapy, but it stopped at halfway because of profuse bleeding. Embryonal Rhabdomyosarcoma is an aggressive tumor, especially in adults. However, there was limited evidence and guideline to diagnose and manage the disease.


embryonal rhabdomyosarcoma prostate

Article Details

How to Cite
Andhika, D. P., & Hardjowijoto, S. (2021). Embryonal Rhabdomyosarcoma of Prostate in Adult: A Rare Case Report. Folia Medica Indonesiana, 57(2), 177–185.


  1. Alanee S, Shukla AR (2009). Bladder malignancies in children aged <18 years: Result from the surveillance epidemiology and end result database. BJU International 106, 557-560.
  2. Arndt CA, Stoner JA, Hawkins DS, et al (2009). Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children’s oncology group study D9803. J Clin Oncol 27, 5182-5188.
  3. Bejar DE, Huh WW (2014). Rhabcomyosarcoma in adolescent and young adult patients: Current perspective. Adolescent Health, Medicine and Therapeutics 5, 115-125.
  4. Burningham Z, Hashibe M, Spector L, et al (2012). The epidemiology of sarcoma. Clinical Sarcoma Research 2, 1-16.
  5. Defoor W, Minevich E, Sheldom C (2002). Unusual bladder mass in children. Urology 60, 911.
  6. Ferrari A, Bisogno G, Casanova M, et al (2002). Paratesticular rhabdomyosarcoma: report from the Italian and German cooperative group. J Clin Oncol 20, 449-55.
  7. Ferrer FA, Isakoff M, Koyle MA (2006). Bladder/prostate rhabdomyosarcoma: Past, present and future. J Urol 176, 1283-91.
  8. Ferrer FA (2016). Pediatric urology oncology: Bladder and testis in Campbell Walsh urology (11th Edition), Netherlands, Elsevier, p P3582-3598.
  9. Jernal A, Siegel R, Xu J, et al (2010). Cancer statistics 2010. CA Cancer J clin 60, 277-300.
  10. Kalmadi S, Raghavan D (2008). Principles of chemotherapy for genitourinary cancer. In: Nargund VH, Raghavan D, Sandler HM. Urological oncology, London, Springer-Verlag, p 194-212.
  11. Kojima Y, Hashimoto K, Ando M, et al (2012). Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy. J Cancer Res Clin Oncol 138, 1249-1257.
  12. Lopez-Beltran A, Montironi R, Vidal-Jimenez A, et al (2007). Pathology of tumors of the urinary bladder. In: Mikuz G. Clinical pathology of urologic tumors, United Kingdom, Informa Healthcare, p 57-89.
  13. Lott SL, Lopez-Beltran A, Montironi R, et al (2007). Soft tissue tumors of the urinary bladder Part II: Malignant neoplasm. Human Pathology 38, 963-977.
  14. Monfardini S, Brunner K, Crowther D, et al (1987). Manual of adult and pediatric medical oncology, Germany, Springer, p 279-285
  15. Rafsanjani KA, Vossough P, Bashardoust A, et al (2007). Survival rate of children with rhabdomyosarcoma and prognostic factor. World J Pediatr 3, 36-40.
  16. Raney RB, Maurer MH, Anderson JR, et al (2001). The intergroup rhabdomyosarcoma study group: Major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. ¬Sarcoma 5, 9-15.
  17. Rodeberg DA, Stoner JA, Garcia-Henriquez N, et al (2011). Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma (RMS): A report from the children’s oncology group. Cancer 117, 2541-2550.
  18. Rosenberg AE (2010). Bones, joints, and soft-tissue tumors. In: Kumar V, Abbas AK, Fausto N, et al. Robbins and Cotran Pathologic Basis of Disease 8th ed, New York, Saunders Company, p 1253-1254.
  19. Swinson S, McHugh K (2011). Urogenital tumours in childhood. Cancer Imaging 11, S48-S64.

Most read articles by the same author(s)